[1]
|
Clayton, D.F. and George, J.M. (1999) Synucleins in synaptic plasticity and neurodegenerative disorders. Journal of Neuroscience Research, 58, 120-129.
doi:10.1002/(SICI)1097-4547(19991001)58:1<120::AID-JNR12>3.0.CO;2-E
|
[2]
|
Bueler, H. (2009) Impaired mitochondrial dynamics and function in the pathogenesis of Parkinson’s disease. Experimental Neurology, 218, 235-246.
|
[3]
|
Zhou, H.Y. and Chen, S.D. (2005) Parkin, Parkin substrates and Parkinson's disease. Progress in Biochemistry and Biophysics, 32, 912-916.
|
[4]
|
Dekker, M.C.J. et al. (2003) Parkinson’s disease: Piecing together a genetic jigsaw. Brain, 126, 1722-1733.
doi:10.1093/brain/awg172
|
[5]
|
Hattori, N. et al. (2000) Autosomal recessive juvenile parkinsonism: A key to understanding nigral dege- neration in sporadic Parkinson’s disease. Neuropathology, 20, S85-S90. doi:10.1046/j.1440-1789.2000.00312.x
|
[6]
|
Wszolek, Z.K. and Markopoulou, K. (1999) Molecular genetics of familial parkinsonism. Parkinsonism & Related Disorders, 5, 145-155.
doi:10.1016/S1353-8020(99)00030-9
|
[7]
|
Schapira, A.H.V. (1997) Pathogenesis of Parkinson’s disease. Baillieres Clinical Neurology, 6, 15-36.
|
[8]
|
Spillantini, M.G. et al. (1997) Alpha-synuclein in Lewy bodies. Nature, 388, 839-840. doi:10.1038/42166
|
[9]
|
Sit, S.Y. (2000) Dopamine agonists in the treatment of Parkinson’s disease—Past, present and future. Current Pharmaceutical Design, 6, 1211-1248.
doi:10.2174/1381612003399581
|
[10]
|
Khan, A. et al. (2005) Metals accelerate the formation and direct the structure of amyloid fibrils of NAC. Journal of Inorganic Biochemistry, 99, 1920-1927.
doi:10.1016/j.jinorgbio.2005.06.018
|
[11]
|
Lashuel, H.A. et al. (2000) Protofilaments, filaments, ribbons, and fibrils from peptidomimetic self-assembly: Implications for amyloid fibril formation and materials science. Journal of the American Chemical Society, 122, 5262-5277. doi:10.1021/ja9937831
|
[12]
|
Jellinger, K.A. (2007) Morphological substrates of parkinsonism with and without dementia: A retrospective clinico-pathological study. Journal of Neural Transmission-Supplement, 72, 91-104.
|
[13]
|
Cabedo, N. et al. (2009) An overview on benzylisoquinoline derivatives with dopaminergic and serotonergic activities. Current Medicinal Chemistry, 16, 2441-2467. doi:10.2174/092986709788682100
|
[14]
|
Montastruc, J.L. et al. (1999) Treatment of Parkinson’s disease should begin with a dopamine agonist. Movement Disorders, 14, 725-730.
doi:10.1002/1531-8257(199909)14:5<725::AID-MDS1003>3.0.CO;2-L
|
[15]
|
Gottwald, M.D. et al. (1997) New pharmacotherapy for Parkinson’s disease. Annals of Pharmacotherapy, 31, 1205-1217.
|
[16]
|
Uitti, R.J. and Ahlskog, J.E. (1996) Comparative review of dopamine receptor agonists in Parkinson's disease. Cns Drugs, 5, 369-388.
doi:10.2165/00023210-199605050-00006
|
[17]
|
Tofaris, G.K. and Spillantini, M.G. (2007) Physiological and pathological properties of alpha-synuclein. Cellular and Molecular Life Sciences, 64, 2194-2201.
doi:10.1007/s00018-007-7217-5
|
[18]
|
Ulmer, T.S. et al. (2005) Structure and dynamics of micelle-bound human alpha-synuclein. Journal of Biological Chemistry, 280, 9595-9603.
doi:10.1074/jbc.M411805200
|
[19]
|
Dedmon, M.M. et al. (2005) Mapping long-range interactions in alpha-synuclein using spin-label NMR and ensemble molecular dynamics simulations. Journal of the American Chemical Society, 127, 476-477.
doi:10.1021/ja044834j
|
[20]
|
Bertoncini, C.W. et al. (2005) Familial mutants of alpha-synuclein with increased neurotoxicity have a destabilized conformation. Journal of Biological Chemistry, 280, 30649-30652.
doi:10.1074/jbc.C500288200
|
[21]
|
I.F. Tsigelny, et al. (2007) Dynamics of alpha-synuclein aggregation and inhibition of pore-like oligomer development by beta-synuclein. FEBS Journal, 274, 1862-1877. doi:10.1111/j.1742-4658.2007.05733.x
|
[22]
|
Krieger, E. et al. (2004) Making optimal use of empirical energy functions: Force-field parameterization in crystal space. Proteins, 57, 678-683. doi:10.1002/prot.20251
|
[23]
|
Kabsch, W. and Sander, C. (1983) Dictionary of protein secondary structure: Pattern recognition of hydro- gen-bonded and geometrical features. Biopolymers, 22, 2577-2637. doi:10.1002/bip.360221211
|
[24]
|
Krieger, E. et al. (2002) Increasing the precision of comparative models with YASARA NOVA—A self-parameterizing force field. Proteins, 47, 393-402.
doi:10.1002/prot.10104
|
[25]
|
Uversky, V.N. et al. (2001) Evidence for a partially folded intermediate in alpha-synuclein fibril formation. Journal of Biological Chemistry, 276, 10737-10744. doi:10.1074/jbc.M010907200
|
[26]
|
Neal, S. et al. (2003) Rapid and accurate calculation of protein H-1, C-13 and N-15 chemical shifts. Journal of Biomolecular Nmr, 26, 215-240.
doi:10.1023/A:1023812930288
|
[27]
|
Bodner, C.R. et al. (2010) Differential phospholipid binding of alpha-synuclein variants implicated in Parkinson’s disease revealed by solution NMR spectroscopy. Biochemistry, 49, 862-871.
doi:10.1021/bi901723p
|
[28]
|
Chandra, S. et al. (2003) A broken alpha-helix in folded alpha-synuclein. Journal of Biological Chemistry, 278, 15313-15318. doi:10.1074/jbc.M213128200
|
[29]
|
Fernandez, C.O. et al. (2004) NMR of alpha- synuclein-polyamine complexes elucidates the me- chanism and kinetics of induced aggregation. Embo Journal, 23, 2039-2046.
|
[30]
|
Georgieva, E.R. et al. (2010) The Lipid-binding Domain of Wild Type and Mutant alpha-Synuclein compactness and interconversion between the broken and extended helix forms. Journal of Biological Chemistry, 285, 28261-28274. doi:10.1038/sj.emboj.7600211
|
[31]
|
Sasakawa, H. et al. (2007) Ultra-high field NMR studies of antibody binding and site-specific phosphorylation of alpha-synuclein. Biochemical and Biophysical Research Communications, 363, 795-799.
doi:10.1016/j.bbrc.2007.09.048
|
[32]
|
Wu, K.P. et al. (2008) Characterization of conforma- tional and dynamic properties of natively unfolded human and mouse alpha-synuclein ensembles by NMR: Implication for aggregation. Journal of Molecular Biology, 378, 1104-1115. doi:10.1016/j.jmb.2008.03.017
|
[33]
|
Wolozin, B. and Golts, N. (2002) Iron and Parkinson’s disease. Neuroscientist, 8, 22-32.
doi:10.1177/107385840200800107
|
[34]
|
Golts, N. et al. (2002) Magnesium inhibits spontaneous and iron-induced aggregation of alpha-synuclein. Journal of Biological Chemistry, 277, 16116-16123.
doi:10.1074/jbc.M107866200
|
[35]
|
Rasia, R.M. et al. (2005) Structural characterization of copper(II) binding to alpha-synuclein: Insights into the bioinorganic chemistry of Parkinson’s disease. Proceedings of National Academy Sciences of U.S.A., 102, 4294-4299. doi:10.1073/pnas.0407881102
|
[36]
|
Latawiec, D. et al. (2010) Modulation of alpha-synuclein aggregation by dopamine analogs. Plos One, 5, e9234.
doi:10.1371/journal.pone.0009234
|
[37]
|
Gatto, N.et al. (2009) Alpha-Synuclein repeat polymorphisms and pesticide exposure in Parkinson's disease. Epidemiology, 20, S124-S124.
doi:10.1097/01.ede.0000362429.51721.26
|
[38]
|
Betarbet, R. et al. (2006) Intersecting pathways to neurodegeneration in Parkinson's disease: Effects of the pesticide rotenone on DJ-1, alpha-synuclein, and the ubiquitin-proteasome system. Neurobiology of Disease, 22, 404-420. doi:10.1016/j.nbd.2005.12.003
|
[39]
|
Cicchetti, F. et al. (2009) Environmental toxins and Parkinson's disease: What have we learned from pesticide-induced animal models? Trends in Phar- macological Sciences, 30, 475-483.
doi:10.1016/j.tips.2009.06.005
|
[40]
|
Richardson, J.R. et al. (2009) Elevated Serum Pesticide Levels and Risk of Parkinson Disease. Archives of Neurology, 66, 870-875. doi:10.1001/archneurol.2009.89
|
[41]
|
Yoon, J. et al. (2009) Simulation studies on the stabilities of aggregates formed by fibril-forming segments of alpha-Synuclein. Journal Biomolecular Structure and Dynamics, 27, 259-270.
|